In the prostate it is present as an inactive pro-form which is activated through the action of KLK2, another kallikrein-related peptidase.
For example, a failure to modulate the activity of kallikreins via the disruption of the protease inhibitor LEKTI causes the debilitating disorder Netherton syndrome.